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ABSTRACT:  Aerosol-assisted atmospheric pressure plasma allows for a one-step synthesis of 
vancomycin-containing nano-capsules. Morphological and chemical analyses were carried out to 
estimate how different discharge parameters affect the plasma deposition process. Nano-capsules size 
and abundance largely depend on the shell precursor content in the gas feed and on the drug 
concentration in the aerosol solution. Based on these results a deposition mechanism is proposed, 
where, interestingly, the key step is the formation of the nano-capsules in the plasma phase. 
Furthermore, the related antibacterial activity is proved against Staphylococcus aureus. Preliminary 
release tests indicate the possible exploitation of the plasma-deposited vancomycin-containing nano-
capsules in the drug delivery field, and systems based on other bioactive molecules can be expected. 
 
  
 1. Introduction 
Nano-capsules are nanometric vescicular systems with a core-shell structure consisting of a cavity 
and a surrounding polymeric membrane or coating. An active compound can be contained inside the 
cavity, in liquid or solid form, or even as a molecular dispersion; the active substance can also be 
carried at the surface of the nano-capsules or imbibed in their polymeric membrane. 
The most widely investigated application of nano-capsules is probably as drug delivery systems.1-3 
Numerous qualities make these systems extremely suitable and vastly used for drug delivery: the 
subcellular size of nano-capsules, for example, allows more efficient uptake of the compounds in 
cells. Other interesting qualities are: improved stability of the active substance in the capsule, 
biocompatibility and biodegradability, high drug-encapsulation efficiency, and shell protection of the 
drug against degradation factors. These systems generally aim at delivering a specific drug where 
required, rather than in the entire body, in low amount rather than in massive quantities, avoiding a 
high risk of developing resistance. The ideal amount of antibacterial compounds released should be 
higher than the Minimum Inhibiting Concentration (MIC) of the target organisms, but well below the 
cytotoxicity threshold. The technological issue concerning nano-capsules synthesis is raising great 
interest. Classical methods for the preparation of nano-capsules are: nano-precipitation, emulsion-
diffusion, double emulsification, emulsion-coacervation, polymer-coating and layer-by-layer 
technique.4 
Nano-capsules containing a bioactive molecule can be considered a biocomposite material with a 
very peculiar morphology. Biocomposite coatings, in general, consist of two fundamental 
components: a bioactive molecule, and a matrix in which the molecule is embedded. The nature of 
the molecule and that of the matrix can be properly selected in order to obtain different coatings for 
a very wide range of applications, including food packaging, 5,6 biosensors,7-15 and bioreactors.16-18 
In the biomaterials field, particularly for tissue engineering and regenerative medicine applications, 
biocomposite coatings are being tested as drug delivery systems, with the aim of providing anti-
 bacterial or enhanced cell-growth properties either on 3D scaffolds19,20 or on flat substrates.21-26 A 
huge variety of processes have been studied to achieve the synthesis of biocomposite coatings; the 
most relevant are: photo-polymerization,27 initiated-Chemical Vapor Deposition (i-CVD),22 3D 
printing,19 micro-dispensing21 and wet chemistry.13,20,28,29 
All the above-mentioned techniques for nano-capsules and biocomposite coatings synthesis present 
in general some drawbacks, especially for the scale-up of the process; for example, multi-step 
protocols are often proposed, that include the use of potentially harmful solvents and reagents. Plasma 
processes may provide a solution to reduce these drawbacks; moreover, they allow fine tuning of 
coating properties without altering the bulk properties of the target material, with limited use of 
chemicals and solvents. 30,31 
A one-step process has been optimized by Palumbo et al. 32 for the plasma deposition of nanometric 
hydrophilic biocomposite coatings embedding active Lysozyme, an antimicrobial enzyme. The 
deposition method is developed in an Atmospheric Pressure Plasma (APP) reactor configured as 
Dielectric Barrier Discharge (DBD), coupled with an atomizer to feed the gas discharge low vapor 
pressure pure liquids, salts solutions and suspensions of nano-particles.32-40,47 This configuration 
allows the deposition on any kind of flat substrate.  
To deposit the biocomposite coatings the aerosol solution atomized into the reactor must contain the 
bioactive molecule dissolved in a suitable solvent. The matrix precursor is also inlet into the reactor, 
as gas or vapor, along with a buffer gas (e.g., He, Ar) to generate the aerosol and to sustain the 
discharge. When the feed passes through the discharge, the precursor and the vapour of the solvent 
are fragmented in radicals and atoms that originate the matrix of the coating; at the same time, 
nanometric drops of the aerosol are present in the plasma environment and participate to the 
deposition process. The bioactive molecule in the droplets is protected against the plasma 
environment, and is found unaltered embedded in the final coating, with retained structure and 
 activity.33-35 Thanks to the mild discharge conditions, aerosol-assisted APP processes enable the use 
of thermo-degradable molecules providing easy-to-handle technical equipment. 
Vancomycin is a glycopeptide antibiotic produced by Streptococcus Orientalis, well known for drug 
delivery applications, with a broad-spectrum activity, including against methicillin-resistant strains 
of Staphylococcus aureus. Vancomycin has often been encapsulated in spherical micro/nanoparticles 
made of polymeric materials such as poly(ε-caprolactone), for bone implants,41 spray dried chitosan,42 
or N-trimethyl chitosan, prepared by single ionic complexation.43 Vancomycin-containing coatings 
produced by electrodeposition 44-46 and adsorption methods46 are also reported. 
We have recently published a communication on the direct synthesis of vancomycin-containing nano-
capsules using an aerosol-assisted APP process.47 It represents an absolute novelty since, for the first 
time, a one-step, easy-to-handle, eco-friendly, plasma process is shown for the synthesis of nano-
capsules embedding a bioactive molecule. As for previous works32, 47 ethylene was selected as 
precursor of the shell of the capsules; vancomycin was selected to be embedded in the capsules from 
an aqueous aerosol, helium was used as buffer and aerosol-forming. Surprisingly, in specific 
experimental conditions, layers of nano-capsules resulted on the zone close to the gas inlet of the 
ground electrode of the DBD, instead of a flat coating embedding the biomolecule.32  
The experiments in this paper highlight more in detail how the variation of some discharge parameters 
can affect the morphology and the deposition mechanism of vancomycin-embedding nano-capsules. 
Furthermore, the optimized materials have been tested for their drug-release properties in water, as 
well as for their antibacterial activity. 
 
2. Experimental Section 
2.1 Materials 
He 99.999% and ethylene 99.95% (Air Liquide) were used as feed gases in the APP deposition 
process. 0-15 mg/mL (corresponding to a maximum concentration of 10-2 mol/l) solutions of 
 vancomycin hydrochloride (MW 1449.2 g/mol; powder, Molecular Biology Grade, from ABCR), in 
water of Milli-Q quality (Millipore, Bedford, MA) were used to generate the aerosol. Water, 
acetonitrile (ACN), formic acid of HPLC grade were used without further purification for HPLC 
analysis. For the release tests and for the determination of the antibacterial activity of the coatings 
Milli-Q quality water was employed. All chemicals used were of analytical grade unless otherwise 
stated.  
Shards (1x1 cm2) of 710 µm thick double-face polished crystalline silicon (100) wafers 
(MicroChemicals GmbH) were used as substrates for the deposition experiments. For the release 
tests, the coatings have been deposited onto 0.25 mm thick Polycarbonate (PC, Goodfellow, 1x1 cm2). 
The analysis of the antibacterial activity has been carried out on films deposited onto titanium disks 
(grade 2, 10 mm dia, VDM metals, Germany) polished with colloidal silica suspension (0.05 μm size, 
Buehler, USA). 
 
2.2 DBD Reactor 
The homemade DBD reactor is the same as the one schematically shown in ref [32,47]. It consists of 
two parallel plates silver electrodes, 5×8 cm2 wide, 5 mm apart, both covered with 0.63 mm thick 
alumina sheets. The electrode set up is confined in a sealed Plexiglas chamber. The aerosol of 0-15 
mg/mL vancomycin aqueous solution was generated with an atomizer (mod. 3067, TSI) working with 
He at a flow rate of 5 slm. Previous works indicated that in this condition a mass flow rate of 136±7 
µg/min of aerosol was obtained. As stated by different authors33, 34 the diameter range of the droplets 
produced by the atomizer, used in the present work, in similar conditions is typically sub-micrometric. 
Ethylene was fed in the chamber at a flow rate of 5-200 sccm, and an auxiliary line allowed He to be 
directly inlet in the chamber when needed. Gas flow rates were controlled by means of electronic 
mass flow controllers (MSK instruments). The gas/aerosol feed was let from the shorter side of the 
reactor, through the plasma zone between the electrodes, and was pumped out by an aspirator located 
 on the opposite side. The Continuous Wave (CW) discharge was ignited between the electrodes using 
a corona power supply (PVM500, Information Unlimited). The electrical properties of the plasma 
were investigated for determining the voltage and the current delivered to the system with a high-
voltage (P6015A, Tektronix) probe and a resistance type current probe, both connected to an 
oscilloscope (TDS 20145C, Tektronix). The average power was obtained by multiplying the energy 
per voltage cycle by the frequency of the applied field; the energy per cycle was calculated from the 
time integral of the current times the voltage in one cycle. The applied peak-to peak voltage was 
always kept at 4 kV at a frequency of 24 kHz, resulting in a power of 1.3 Wcm-2, in the experimental 
conditions used in this work. Before each deposition experiment, a cleaning step of the electrodes 
was performed by igniting for 5 min a discharge fed with a water aerosol carried by He with a flow 
rate of 5 slm. Substrates were positioned on the bottom electrode, always within 3 cm close to the 
inlet of the feed, and the chamber was purged with a 5 slm He stream for 5 min. To better understand 
the deposition process mechanism, the discharge duration has been tuned in the range 1-13 min. 
Discharges ignited in Pulsed Mode (PM) were also investigated, in this case a pulse generator was 
controlling the power supply with an on-time of 40 ms and an off time of 80 ms, hence a duty cycle 
of 33%.   
With the purpose of modulating the release rate of vancomycin from the coating and in the 
antibacterial essays, in some samples an additional layer (100 nm thick) has been deposited on top of 
the bioactive coating, to act as a diffusion barrier layer. Such top coating has been deposited in a 
continuous discharge fed with 20 sccm ethylene and 5 slm He for 3 min. 
 
2.3 Chemical and morphological characterization of the samples 
Fourier Transform Infrared Spectroscopy (FT-IR) was carried out to characterize the bulk of the 
coatings. FT-IR spectra (32 scans per analysis, 4 cm-1 resolution) were obtained in transmission mode 
with a Vertex 70V Bruker spectrometer. The spectrometer was evacuated to less than 150 Pa for 10 
 min before each acquisition. Spectra were normalized by the maximum intensity of the O-H/N-H 
stretching band at 3400 cm-1.  
Scanning Electron Microscopy (SEM) was carried out to analyse the morphology of the samples with 
a Zeiss Supra 40 equipped with a Gemini field-effect emission gun. Analyses were carried out at an 
extraction voltage of 3 kV, onto samples sputter coated with a 20 nm thick layer of chromium. For 
each acquisition the brightness, the contrast and the working distance (varying in the range of 2-4 
mm) have been optimized.  
Static Water Contact Angle (WCA) measures were performed with a Rame´-Hart Inc, 100-00-230 
goniometer (5ml drop, double distilled water).  
 
2.4 Vancomycin release tests 
Plasma processed samples 1x2 cm2 wide were put into 12-well Iwaki polystyrene plates with flat base 
(Sterilin Limited, Newport, UK), covered with 800 μL of water, and incubated at room temperature. 
The amount of vancomycin released was monitored collecting 300 μL of supernatant, at different 
soaking time, up to 4 days. Every withdrawn aliquot of liquid was refurbished with 300 μL of fresh 
distilled water, to keep the dipping volume constant. The release solution was analysed with a 
spectrophotometer UV-2401PC (Shimadzu) set at 280 nm. The release solution was also analysed by 
Mass Spectrometry Liquid Chromatography, to confirm the integrity of the released vancomycin 
molecule. A C18 column was used (2.1 m length, 250 µm dia, 1.7 μm packing, 0.2 mL/min flow rate) 
with a 0.1% formic acid H2O/ACN 95/5 solution as mobile phase. 
 
2.5 Antibacterial activity of the coatings 
Two different tests have been performed. For the Agar diffusion test a bacteria suspension 
(Staphylococcus aureus, CCUG 15915, Culture Collection of the University of Göteborg, Sweden) 
incubated overnight was diluted to an absorbance of 0.20±0.01 at 600 nm, giving approximately 1·108 
 CFU/mL. An aliquot of 100 μL of the suspension was seeded on the agar plate and the plasma coated 
Ti samples were placed upside down in the plate. The plates were then incubated overnight at 37 ºC 
and the zone where the growth of bacteria is inhibited was measured around the samples.  
The growth inhibition (double-well) test, instead, was performed in order to evaluate the dynamic 
antibacterial activity of eluents from the samples. A 48 wells plate (Nunc) with adjacent pair wells 
connected was used: one for the titanium sample and the other one for the measurement of the bacteria 
growth curve by UV-vis spectrophotometer, as previously reported.49 Bacteria for this assay were 
grown overnight and diluted to an optical density of 0.02, corresponding to 106 CFU/mL. A 1mL 
aliquot of suspension was placed in each well and the absorbance at 600 nm was monitored with a 
multiplate reader (Multimode microplate reader, Synergy™ HTX) every 10 min. Before each 
measurement, the plate was shaken for 3 s to ensure the homogeneity of the suspension. 
 
3. Results and discussion 
 
3.1 Characterization of the coatings 
In our previous work 47, we presented the core-shell organization of the vancomycin-containing 
nano-capsules constituting the APP deposited coatings obtained from continuous and modulated 
plasma. The structure of the capsules could be easily detected and it was also observed that, when 
deposited in continuous mode, the spherical structures appeared bigger than those formed in DBDs 
ignited in pulsed mode, where taller aggregates of slightly smaller spheres were formed (Figure 1a 
and 1b). After immersion of the samples in water, the PM coating largely delaminated47 , whereas the 
CW one showed just a 17% decrease in thickness, and moreover in the latter some of the spheres 
opened revealing a cavity, or collapsed upon themselves, as clearly shown in Figure 1c. Confocal 
microscopy observations of the coatings synthesized by feeding the discharge with an aerosol of a 
 fluorescein solution, instead of vancomycin, demonstrated the presence of the aerosol solute inside 
the nano-capsules.  
Figure 2 shows SEM images of coatings deposited in CW when the C2H4 flow rate was changed in 
the range 5-200 sccm. It can be observed that, the density of nano-capsules at the surface of the 
coating increases with the ethylene flow rate; furthermore, at a C2H4 flow rate of 200sccm their 
average diameter is drastically lower. 
Figure 1 – Cross section SEM image of coatings plasma deposited (20 sccm ethylene, 5 slm He, 15 
mg/ml of vancomycin solution) in a) CW (inset top view) and b) PM condition. c) Top view SEM 
image of a CW plasma deposited coating after 60 min immersion in water. Adapted from ref. 47 by 
permission of The Royal Society of Chemistry.  
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Figure 2 – SEM images of coatings deposited in continuous mode (15 mg/ml vancomycin solution, 
13 min), at different ethylene flow rate: (a) 5 sccm, (b) 20 sccm, (c) 50 sccm, (d) 200 sccm. b)  adapted 
from ref. 47 by permission of The Royal Society of Chemistry 
 
On the other hand, Figure 3 clearly shows that, keeping the flow rate of ethylene at 20 sccm and 
increasing the deposition time in the range 1-13 min, the surface of the coatings gets increasingly 
crowded of nano-capsules. 
A qualitative evaluation of Figures 4a-c shows that, when varying the concentration of vancomycin 
in the aerosol-forming solution in the range 5-15 mg/mL, the morphology of the coating stays 
unchanged. However, as shown in Figure 4d, a further lowering of the concentration to 1 mg/mL 
impacts, indeed, the morphology of the coating decreasing the density and size of the spheres. 
Capsules are absent when the same plasma process is carried out with vancomycin-free aerosols (not 
shown). 
  
Figure 3 – SEM images of coatings deposited in continuous mode (15 mg/ml of vancomycin solution, 
20 sccm of ethylene) at different discharge duration: (a) 1 min, (b) 5 min, (c) 10 min, (d) 13 min. d)  
adapted from ref. 47 by permission of The Royal Society of Chemistry 
 
Figure 4 – SEM images of coatings deposited in continuous mode (20 sccm ethylene, 13 min), with 
an aerosol solution containing (a) 15, (b) 10, (c) 5, (d) 1 mg/ml of vancomycin. a)  adapted from ref. 
47 by permission of The Royal Society of Chemistry 
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 The results shown so far led us to hypothesize the deposition mechanism schematically illustrated in 
Figure 5 for the nano-capsules formation; the advancement of the deposition process is a function, 
amongst other parameters, of the distance from the feed inlet and the deposition time. In particular, it 
is possible to identify three main steps:  
I. ethylene molecules enter in the plasma zone with He carrier (not shown in the scheme), along 
with the aerosol droplets containing water and vancomycin;  
II. partial evaporation from the aerosol droplets and fragmentation of water takes place in the 
plasma zone, along with the fragmentation/activation of the ethylene precursor, giving rise to 
polymerization both at the surface of the substrate and at the surface of the aerosol droplets; 
at the same time the droplets, coated and uncoated, adsorb at the surface of the substrate where 
the polymerization proceeds; 
III. The droplets adsorbed at the surface of the substrate become partially covered by and 
embedded in the growing hydrocarbon-like matrix. At the end of the deposition process, the 
overall deposited layer results composed by spherical nano-capsules partially embedded in or 
leant on a flat film; the spheres are composed by a vancomycin-containing core and a 
hydrocarbon polymer-like shell. 
 
 Figure 5 – Scheme of the hypothesized deposition mechanism. 
 
 
The SEM morphological analyses illustrated in this paper well support the hypothesis formulated on 
the aerosol-assisted APP deposition mechanisms of the nano-capsule layer. It has to be stressed that 
the deposition of the nano-capsules occurs, also when other kind of solute is used in the aerosol, in 
the plasma zone close to the feed inlet, where the feed meets the discharge. More pieces of discussion 
on the deposition mechanism are delivered below.  
If we consider the effect of the ethylene flow rate shown in Figure 2, for example, the low density of 
spheres obtained at 5 sccm of C2H4 could be explained by the low amount of polymer precursor 
fragments available to coat all nanodroplets in the discharge; most of the water evaporates from the 
nanodroplets, and this results in less spheres at the surface of the substrate. When 200 sccm of C2H4 
are fed, instead, the density of precursor fragments is high enough to initiate a fast polymerization at 
the surface of the droplets, even the small ones, before they evaporate or aggregate; this results in a 
higher number of spheres in the deposited layer, with a lower diameter compared to coatings 
deposited feeding the plasma with 20 and 50 sccm C2H4.  
Regarding the effect of the deposition time shown in Figure 3 we hypothesize that, as the duration 
time of the discharge proceeds, more spheres are produced in the plasma zone and lean on the 
substrate, with the small ones that adhered on the bare substrate at the beginning of the deposition 
process resulting covered and embedded by the growing matrix.  
The question could arise about the fate of water, as to whether there is liquid water in the capsules. It 
is hard to give an exhaustive answer, for the lack of suitable chemical imaging spatially resolved 
techniques, at the best of the authors’ knowledge. However, it is possible to state that though water 
can be present in the capsules, it should not be in liquid state. In fact, in such a case, once in the 
 ultrahigh vacuum of SEM, capsules should burst during the analysis or at least broken capsules 
residues should be observed. But such phenomena have never been noticed.  
The presence of a solute in the aerosol solution appears to be also relevant to the formation of the 
nano-capsules, as shown in Figure 4. Their number and dimension remain constant first, and then 
decreases with the concentration of vancomycin in the solution, finally absent when a pure water 
aerosol is used. This effect could probably be explained with the different stability in the plasma zone 
of nanodroplets containing different amount of vancomycin chloride.  
It should be considered that, as reported in our previous paper, 47 nano-capsules were also observed 
when the aerosol solution contained fluorescein, and Chun-Ping Hsiao et al. 50 reported the presence 
of similar features when the atomizer was fed with a lysozyme solution. The work carried out up to 
now, therefore, demonstrates that the presence of a solid solute in the aerosol solution is a key factor 
in the formation of the spheres. Since the vancomycin concentration used in our experiments is not 
enough to substantially affect water vapor tension, some effects due to the segregation of the solute 
at the surface of the nanodroplets could be taken into account. We hypothesize that vancomycin 
segregates at the surface of the nanodroplets and increases locally the density of the solution; in this 
way, the droplets surface can better sustain the coating formation. At low or zero concentration, this 
effect is negligible, thus the coating shell cannot easily form and the water droplet can evaporate or 
spread over the sample. We can suppose that such molecules can segregate at the drop/gas interface 
for 2 main reasons: 
1) Due to hydrophobic forces leading to orientation of the hydrophobic part of the molecule 
towards the interface, as characteristic of surfactants 
2) Due to electrostatic forces. The drop surface, as in contact with plasma, is likely negatively 
charged, thus dipoles or ions would orient, at the interface according to the correct polarity. 
 Two considerations  support the importance of these phenomena. The mentioned molecules are polar 
or even in ionic form: Fluoresceine and vancomycin are salts, amimo groups of lysozyme in water 
should be protonized. Furthermore, since it is likely that during the transportation water in the drops 
would decrease by evaporation, the solute concentration will grow and both phenomena can become 
more important. Further experiments are necessary for a better comprehension of the role of the solute 
in stabilizing the droplets. 
In order to get some insights into the chemistry of the coating and to verify the presence of 
vancomycin, FT-IR, WCA and XPS analyses have been carried out. In Figure 6 the normalized 
absorption FT-IR spectra of films deposited with a CW and a PM plasma are reported, and the FT-IR 
spectrum of drop-casted vancomycin. Tracks b and c refer to coatings with embedded nano-capsules. 
A comparison is done with the spectrum of the film obtained by feeding the CW plasma with ethylene 
and water aerosol (Figure 6a) and the spectrum of vancomycin solution drop-casted on the substrate 
(Figure 6d). All deposited coatings exhibit a common hydrocarbon backbone, revealed by the 
absorption bands relative to CH2 and CH3 stretching (2964-2933 cm-1), CH2 bending (1430-1370 cm-
1). Further, the samples, even when vancomycin is absent in the feed, show bands relative to C=O 
(1712-1658 cm-1) and OH stretching (3371 cm-1), testifying the action of oxidized water fragments 
(O atoms, OH radicals) in the deposition mechanism. The spectra of the coatings containing 
vancomycin exhibit the characteristic absorption bands of vancomycin: in particular, the bands at 
3300 cm-1 and 1502 cm-1, due to NHx group and the one at 1232 cm-1. Such bands, though not specific, 
are likely related to the presence of vancomycin. Since these absorption bands are more intense in the 
spectra of the coating plasma deposited in PM conditions, it can be inferred that in this case films 
with a higher vancomycin (or vancomycin-like)/hydrocarbon relative content have been obtained.  
  
Figure 6 - FT-IR transmission spectra of coating deposited (20 sccm of C2H4) in different conditions 
on Silicon substrates: a) feeding the CW plasma with C2H4 and water aerosol, b) feeding the CW 
plasma with C2H4 and vancomycin containing aerosol (15 mg/ml), c) feeding the PM (DC 33%) 
plasma with C2H4 and vancomycin containing aerosol (15 mg/ml), d) drop casted vancomycin. 
 
This could be expected since in a pulsed process, part of the time the plasma is off and as a matter of 
fact, the deposition of the matrix is drastically reduced. Off time likely does not affect vancomycin 
deposition, which is mostly transferred to the sample by condensation, hence, the drug deposition rate 
can be considered independent from the pulse or continuous condition. As a result, the coating is 
enriched in vancomycin passing from continuous to pulse mode.  
The higher vancomycin/hydrocarbon IR absorption bands ratio in the PM coating is confirmed by 
WCA and XPS analyses, whose results are reported in table 1. Both PM and CW deposited coatings 
show, indeed, a hydrophilic character, however the PM coatings shows much lower static WCA, while 
the CW coatings, either embedding vancomycin or not, has close water contact angle. 
Concerning XPS analysis, the atomic composition does not change very much with the experimental 
condition investigated, except when comparing CW and PM. Notably, in continuous mode no 
heteroatoms relative to vancomycin are detected. The reason is clear:  
 i) as reported in table 1, N and Cl content in vancomycin is low and, considering that in the 
coatings the drug is diluted in the matrix, the heteroatoms atomic concentration will be much lower 
and below the detection limit for XPS. 
ii) the escape depth for XPS is much lower than 10nm, and if vancomycin is mostly in the core 
of the capsules, it cannot be revealed. 
The latter point is important and useful for the discussion on nano-capsules structure since it can 
further prove the core-shell structure of the features found. 
On the other hand, in PM some chlorine and nitrogen can be revealed. This can be ascribed to the 
likely higher concentration of vancomycin in the coating, and much more to the possibility that in 
PM some vancomycin just adsorb on the coating during the off time, without being embedded in the 
capsules. Thus, in this kind of samples, vancomycin is more accessible to XPS.  
 
Table 1. XPS atomic concentration and water contact angle of coatings deposited in CW (with and 
without vancomycin) and in PM (5 slm of He, 20 sccm of ethylene and 15 mg/ml of vancomycin in 
the aerosol). Error onto WCA of 3°. 
Sample CXPS (%) OXPS (%) NXPS (%) ClXPS (%) WCA (°) 
theoretical 65 24 9 2 // 
CW w/o 
vancomycin 
81±4 19±1 // // 69 
CW with 
vancomycin 
76.0±4.0 24.0±2.0 // // 59 
PM with 
vancomycin 
70.0±3.0 26.0±3.0 3.7±0.3.0 0.3±0.1 20 
 
Since the main application of the coating is as a drug delivery system, the kinetics of the vancomycin 
release from the coating was monitored. Water has been used as medium for the release test since the 
coating is supposed to be, in its end use, in contact with aqueous environment.  
  
Figure 7 - Percentage of released vancomycin from 1µm thick coatings deposited (5 slm of He, 20 
sccm of ethylene, 15 mg/ml of vancomycin in the aerosol) in PM without (dash) and with addition 
of top coating (solid), in CW without (dot), and with the addition of top coating (dash-dot).  
 
The release assay was conducted on 1µm thick composite coatings deposited in CW and in PM 
conditions, both with and without the addition of a top coating. In Figure 7 it can be appreciated that 
coatings deposited in pulse mode release vancomycin faster, and the addition of a protective layer has 
no effect on the kinetics. On the other hand, the drug release from the CW film is slower and, in 
particular, the percentage of released vancomycin is 75% after 100 min, less than 50% with a top 
coating, while in the same time for the PM case the release is around 90%. Much more, it can be 
observed that the continuous mode coating takes more than 2 days to release all the leachable drug 
when the top layer is present. These results can depend on the morphology of the PM film, richer in 
asperities, offering a higher surface area to contact with water, which makes the release easier and 
reduces the ability of the top coating to conformably cover the sample surface. 
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 Finally, from the release test it has been evaluated that in the case of the PM coating the amount of 
total vancomycin released is about 94 μg/cm2, higher than the estimated amount for the CW 
deposition, 23 μg/cm2. Such difference confirms what has been found with IR investigation, due to 
aerosol solution condensation during the plasma off time in pulse mode. 
Going back to the SEM pictures reported in Fig 1c, it can be observed that though most of vancomycin 
is released in 1 h, most of theof the capsules remains whole. This could indicate that capsule 
collapsing or cracking do not happen for all the structures upon water immersion, as most of them 
can stand the loss of the drug. 
To further prove the presence of vancomycin in the release extract, a coating has been deposited for 
23 min in PM. Then the sample has been immersed for 30 min in distilled water and an aliquot of the 
supernatant analysed with HPLC-MS. An elution peak at the same time as standard vancomycin has 
been found for the release sample with the mass of 1443,43 amu.  
 
 
3.2 Antibacterial activity assay 
The antibacterial activity was evaluated by the agar diffusion and growth test for coatings deposited 
onto Ti discs with a thickness of 1µm and a 100 nm barrier coating on top. In the agar diffusion test, 
it can be observed that the inhibition halo is not evident when the coating is just the matrix, without 
the drug (Figure 8a); on the other hand, samples coated with vancomycin-containing films give origin 
to an inhibition zone whose diameter is respectively 3.2 ± 0.1 cm for the CW coating (Figure 8b) and 
3.8 ± 0.5 cm for the PM coating (Figure 8c). 
  
 Figure 8 - Inhibition halos in agar from Ti disks coated a) in CW using a vancomycin-free water 
aerosol, b) in CW and c) in PM with a vancomycin containing aerosol. 1µm thick coatings deposited 
with 5 slm of He, 20 sccm of ethylene and 15 mg/ml of vancomycin in the aerosol. The composite 
coatings had a 100 nm barrier coating on top as described for fig.7. 
 
 
The bacteria growth rate test results are reported in Figure 9: higher absorbance values of the solutions 
correspond to highest bacterial concentration. It can be observed that the vancomycin-free coating (a) 
does not inhibit the bacterial growth, as well as the bare Titanium disk (b). Both coatings containing 
vancomycin (c and d) completely inhibit the growth of bacterial cells. Hence, both bacterial test 
considered confirm the antimicrobial activity of the coatings prepared, through release of the drug. 
 
Figure 9 – Growth curves from a) a coating deposited in CW with a vancomycin-free water aerosol, 
b) Titanium disks, c) a coating deposited in CW with a vancomycin-containing aerosol, d) a coating 
deposited in PM with a vancomycin-containing aerosol. The plasma deposited coatings have been 
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 deposited with a thickness of 1µm with 5 slm of He, 20 sccm of ethylene and 15 mg/ml of vancomycin 
in the aerosol. The composite coatings had a 100 nm barrier coating on top as described for fig.7. 
 
 
4. Conclusions 
The plasma deposition of vancomycin-containing capsules has been investigated and optimized in 
this work. The morphological SEM analysis seems to indicate that this deposition process mainly 
depends onto the flow rate of the matrix precursor, C2H4, and the concentration of drug in the aerosol 
solution. In particular, a solid solute in this solution is necessary, otherwise no capsules appear. It is 
likely that plasma polymerization of the matrix starts around the aerosol droplets, trapping the 
vancomycin inside the capsule. FTIR and liquid chromatography confirm the presence of vancomycin 
in the composite coatings. 
The kinetics release study has proven that the addition of a barrier top layer can slow down the drug 
release rate, only in the case of coatings deposited in continuous mode, likely because of the most 
complex morphology of PM films. A release, lasting  two days, has been obtained with a 100 nm 
thick top coating. 
Bacteria agar diffusion and growth test confirmed the antibacterial activity of the deposited materials, 
opening up a route to the preparation of drug delivering systems loaded with vancomycin. Despite 
the complexity of the mechanism hypothesized, this work allowed for a better comprehension of this 
unique deposition process forming nano-capsules containing drug, by means of atmospheric pressure 
plasma.  
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 Table of Content 
Drug can be encapsulated in plasma polymerized nano-vescicles by means of aerosol-assisted 
atmospheric pressure plasma in a dielectric barrier discharge configuration. This is hereby proved for 
vancomycin containing composite coatings, evidencing the morphology of nanocapsule with a core-
shell structure. The growth mechanism proposed is based on the hypothesis that the capsules shell is 
plasma polymerized around the aerosol nano-droplets before sticking on the substrate. Once deposited 
such nano-capsules formed film is able to release the drug in water, and much more the antibacterial 
activity is maintained, as demonstrated against Staphylococcus aureus.  
 
 
